Wall Street brokerages forecast that Tenax Therapeutics, Inc. (NASDAQ:TENX) will post earnings of ($0.13) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Tenax Therapeutics’ earnings. Tenax Therapeutics posted earnings per share of ($0.23) in the same quarter last year, which would suggest a positive year over year growth rate of 43.5%. The firm is scheduled to issue its next earnings results on Monday, September 20th.
According to Zacks, analysts expect that Tenax Therapeutics will report full-year earnings of ($1.58) per share for the current fiscal year, with EPS estimates ranging from ($1.71) to ($1.44). For the next year, analysts anticipate that the business will post earnings of ($0.09) per share, with EPS estimates ranging from ($0.56) to $0.38. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that that provide coverage for Tenax Therapeutics.
Tenax Therapeutics (NASDAQ:TENX) last posted its quarterly earnings data on Monday, August 16th. The specialty pharmaceutical company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.03.
Several large investors have recently modified their holdings of TENX. Renaissance Technologies LLC boosted its stake in shares of Tenax Therapeutics by 75.1% during the 1st quarter. Renaissance Technologies LLC now owns 747,832 shares of the specialty pharmaceutical company’s stock valued at $1,421,000 after buying an additional 320,800 shares during the period. Vanguard Group Inc. boosted its stake in shares of Tenax Therapeutics by 100.3% during the 2nd quarter. Vanguard Group Inc. now owns 356,347 shares of the specialty pharmaceutical company’s stock valued at $742,000 after buying an additional 178,455 shares during the period. State Street Corp acquired a new stake in shares of Tenax Therapeutics during the 2nd quarter valued at $296,000. Dimensional Fund Advisors LP acquired a new stake in shares of Tenax Therapeutics during the 1st quarter valued at $115,000. Finally, Morgan Stanley boosted its stake in shares of Tenax Therapeutics by 1,932,400.0% during the 2nd quarter. Morgan Stanley now owns 38,650 shares of the specialty pharmaceutical company’s stock valued at $80,000 after buying an additional 38,648 shares during the period. 21.93% of the stock is owned by institutional investors.
Tenax Therapeutics Company Profile
Tenax Therapeutics, Inc, a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. The company develops levosimendan, which completed a phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction; and Imatinib, a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension.
Further Reading: Dual Listing What You Need to Know
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.